FTC released an interim report criticizing the negative impact pharmacy benefit manager (PBMs) have on prescription drug prices and access.| Bio.News
PBM industry that has driven reimbursement so low as to threaten the viability of local community pharmacies.| Bio.News
Rather than incentivizing PBMs to seek out medicines with high prices, there is a movement to “delink” price and PBM compensation.| Bio.News
PBMs save money with “step therapy,” which tries to displace a provider’s clinical judgment in favor of the medicine selected by the PBM.| Bio.News